Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

LORAZEPAM vs LORLATINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

LORAZEPAM vs LORLATINIB: Safety Overview

Metric LORAZEPAM LORLATINIB
Total FAERS Reports 33,404 5,508
Deaths Reported 6,187 1,542
Death Rate 18.5% 28.0%
Hospitalizations 15,431 1,232
Average Patient Age 49.8 yrs 56.5 yrs
% Female Patients 60.8% 54.0%
FDA Approval Date Approved Prior to Jan 1, 1982 Nov 2, 2018
Manufacturer Hikma Pharmaceuticals USA Inc. Pfizer Laboratories Div Pfizer Inc
Route INTRAMUSCULAR ORAL
Marketing Status Prescription Prescription